Research ExplorerPublicationsKinetics and correlates of the neutralizing antibody respons...

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Standard

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. / Vanshylla, Kanika; Cristanziano, Veronica Di; Kleipass, Franziska; Dewald, Felix; Schommers, Philipp; Gieselmann, Lutz; Gruell, Henning; Schlotz, Maike; Ercanoglu, Meryem S.; Stumpf, Ricarda; Mayer, Petra; Zehner, Matthias; Heger, Eva; Johannis, Wibke; Horn, Carola; Suárez, Isabelle; Jung, Norma; Salomon, Susanne; Eberhardt, Kirsten Alexandra; Gathof, Birgit; Fätkenheuer, Gerd; Pfeifer, Nico; Eggeling, Ralf; Augustin, Max; Lehmann, Clara; Klein, Florian.

In: CELL HOST MICROBE, Vol. 29, No. 6, 09.06.2021, p. 917-929.e4.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Vanshylla, K, Cristanziano, VD, Kleipass, F, Dewald, F, Schommers, P, Gieselmann, L, Gruell, H, Schlotz, M, Ercanoglu, MS, Stumpf, R, Mayer, P, Zehner, M, Heger, E, Johannis, W, Horn, C, Suárez, I, Jung, N, Salomon, S, Eberhardt, KA, Gathof, B, Fätkenheuer, G, Pfeifer, N, Eggeling, R, Augustin, M, Lehmann, C & Klein, F 2021, 'Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans', CELL HOST MICROBE, vol. 29, no. 6, pp. 917-929.e4. https://doi.org/10.1016/j.chom.2021.04.015

APA

Vanshylla, K., Cristanziano, V. D., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., Mayer, P., Zehner, M., Heger, E., Johannis, W., Horn, C., Suárez, I., Jung, N., Salomon, S., Eberhardt, K. A., ... Klein, F. (2021). Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. CELL HOST MICROBE, 29(6), 917-929.e4. https://doi.org/10.1016/j.chom.2021.04.015

Vancouver

Vanshylla K, Cristanziano VD, Kleipass F, Dewald F, Schommers P, Gieselmann L et al. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. CELL HOST MICROBE. 2021 Jun 9;29(6):917-929.e4. https://doi.org/10.1016/j.chom.2021.04.015

Bibtex

@article{026290b9ef8940e3b03b79078bc1b210,
title = "Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans",
abstract = "Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% of individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2 neutralization, with these {"}elite neutralizers{"} also possessing SARS-CoV-1 cross-neutralizing IgG. Multivariate statistical modeling revealed age, symptomatic infection, disease severity, and gender as key factors predicting SARS-CoV-2-neutralizing activity. A loss of reactivity to the virus spike protein was observed in 13% of individuals 10 months after infection. Neutralizing activity had half-lives of 14.7 weeks in serum versus 31.4 weeks in purified IgG, indicating a rather long-term IgG antibody response. Our results demonstrate a broad spectrum in the initial SARS-CoV-2-neutralizing antibody response, with sustained antibodies in most individuals for 10 months after mild COVID-19.",
keywords = "Adolescent, Adult, Aged, Antibodies, Neutralizing/immunology, Antibodies, Viral/immunology, COVID-19/immunology, Cohort Studies, Female, Humans, Immunoglobulin G/immunology, Male, Middle Aged, SARS-CoV-2, Time Factors, Young Adult",
author = "Kanika Vanshylla and Cristanziano, {Veronica Di} and Franziska Kleipass and Felix Dewald and Philipp Schommers and Lutz Gieselmann and Henning Gruell and Maike Schlotz and Ercanoglu, {Meryem S.} and Ricarda Stumpf and Petra Mayer and Matthias Zehner and Eva Heger and Wibke Johannis and Carola Horn and Isabelle Su{\'a}rez and Norma Jung and Susanne Salomon and Eberhardt, {Kirsten Alexandra} and Birgit Gathof and Gerd F{\"a}tkenheuer and Nico Pfeifer and Ralf Eggeling and Max Augustin and Clara Lehmann and Florian Klein",
note = "Copyright {\textcopyright} 2021 Elsevier Inc. All rights reserved.",
year = "2021",
month = jun,
day = "9",
doi = "10.1016/j.chom.2021.04.015",
language = "English",
volume = "29",
pages = "917--929.e4",
journal = "CELL HOST MICROBE",
issn = "1931-3128",
publisher = "Cell Press",
number = "6",

}

RIS

TY - JOUR

T1 - Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

AU - Vanshylla, Kanika

AU - Cristanziano, Veronica Di

AU - Kleipass, Franziska

AU - Dewald, Felix

AU - Schommers, Philipp

AU - Gieselmann, Lutz

AU - Gruell, Henning

AU - Schlotz, Maike

AU - Ercanoglu, Meryem S.

AU - Stumpf, Ricarda

AU - Mayer, Petra

AU - Zehner, Matthias

AU - Heger, Eva

AU - Johannis, Wibke

AU - Horn, Carola

AU - Suárez, Isabelle

AU - Jung, Norma

AU - Salomon, Susanne

AU - Eberhardt, Kirsten Alexandra

AU - Gathof, Birgit

AU - Fätkenheuer, Gerd

AU - Pfeifer, Nico

AU - Eggeling, Ralf

AU - Augustin, Max

AU - Lehmann, Clara

AU - Klein, Florian

N1 - Copyright © 2021 Elsevier Inc. All rights reserved.

PY - 2021/6/9

Y1 - 2021/6/9

N2 - Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% of individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2 neutralization, with these "elite neutralizers" also possessing SARS-CoV-1 cross-neutralizing IgG. Multivariate statistical modeling revealed age, symptomatic infection, disease severity, and gender as key factors predicting SARS-CoV-2-neutralizing activity. A loss of reactivity to the virus spike protein was observed in 13% of individuals 10 months after infection. Neutralizing activity had half-lives of 14.7 weeks in serum versus 31.4 weeks in purified IgG, indicating a rather long-term IgG antibody response. Our results demonstrate a broad spectrum in the initial SARS-CoV-2-neutralizing antibody response, with sustained antibodies in most individuals for 10 months after mild COVID-19.

AB - Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% of individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2 neutralization, with these "elite neutralizers" also possessing SARS-CoV-1 cross-neutralizing IgG. Multivariate statistical modeling revealed age, symptomatic infection, disease severity, and gender as key factors predicting SARS-CoV-2-neutralizing activity. A loss of reactivity to the virus spike protein was observed in 13% of individuals 10 months after infection. Neutralizing activity had half-lives of 14.7 weeks in serum versus 31.4 weeks in purified IgG, indicating a rather long-term IgG antibody response. Our results demonstrate a broad spectrum in the initial SARS-CoV-2-neutralizing antibody response, with sustained antibodies in most individuals for 10 months after mild COVID-19.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antibodies, Neutralizing/immunology

KW - Antibodies, Viral/immunology

KW - COVID-19/immunology

KW - Cohort Studies

KW - Female

KW - Humans

KW - Immunoglobulin G/immunology

KW - Male

KW - Middle Aged

KW - SARS-CoV-2

KW - Time Factors

KW - Young Adult

U2 - 10.1016/j.chom.2021.04.015

DO - 10.1016/j.chom.2021.04.015

M3 - SCORING: Journal article

C2 - 33984285

VL - 29

SP - 917-929.e4

JO - CELL HOST MICROBE

JF - CELL HOST MICROBE

SN - 1931-3128

IS - 6

ER -